Fate Therapeutics, Inc., CRISPR Therapeutics AG, M&T Bank Corp made yesterday's list of top gainers.

Leading equity indices in the US rose as Dow Jones closed the day at 34,000, having gained 0.3%. S&P 500 closed the day at 4,151.32, having gained 0.33%.

More data out yesterday as United States TIC Net Long-Term Transactions (Feb) released yesterday at 20:00 UTC with a figure of 71 billion, while the previous figure was 31.9 billion.

Have a look at yesterday's biggest gainers:

M&T Bank | Up 7.78% to $125.66 yesterday

The US commercial bank traded at $125.66 yesterday, after making its biggest single-day jump of $9.07 (7.78%) since October 2022. The US commercial bank traded as high as $191.41 before shedding 34.8% lower over the past six months. So far this year, it has been doing worse than the S&P by 21.79%. The US bank's market cap currently stands at $21.12 billion with an average daily volume of 2.43 million shares.

+7.67%: Enphase gains 7.67% within $214.78 to $229.23 daily range

The clean energy tech developer rose as high as $229.23 before giving up its gains and dropping back to $224.92 before the close on yesterday. Enphase Energy's market cap is currently $30.81 billion with an average daily trading volume of 3.71 million shares. So far this year, it has been under-performing the S&P by 19.54%.

Enphase is trading in a $214.78 – $229.23 range prior to its earnings announcement.

CRISPR Therapeutics | Up 7.91% to $54.29 yesterday

CRISPR Therapeutics gained $3.98 and closed above the $51 level for the first time in 6 weeks and a half. The gene-editing biotech company has gained 35.9% since its lowest print of $39.19 earlier this year. So far this year, it has performed better than the Nasdaq by 21.29%. Currently, the Swiss biotechnology company has a market capitalization of $4.27 billion with an average daily volume of 1.27 million shares. CRISPR Therapeutics has a forecast of $1.62 million with an EPS of $-2.32.

+9.65%: Fate Therapeutics ended yesterday at $6.59, a 9.65% increase

Fate Therapeutics ended Friday's session at $6. yesterday started with an increase to $6.66, but dropped back and closed at $6.59. Currently, the cellular immunotherapy developer has a market capitalization of $646.89 million with an average daily volume of 3.24 million shares. So far this year, it has been doing worse than the Nasdaq by 51.94%.